EBRCZ
EBR SYSTEMS INC NPV CDI 1:10.6037
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
351.79MP/E (TTM)
-Basic EPS (TTM)
-0.12Dividend Yield
0%Recent Filings
10-Q
10-Q
Q2 FY2025 results
EBR Systems notched its first revenue in Q2 FY2025, posting $169,704 from WiSE CRT System sales—up from zero last year—thanks to April's FDA approval for U.S. commercial use in tough cardiac cases. Gross margin hit 50.0%, though excluding prior clinical inventory it'd dip negative; operating loss widened to $11.1M from $10.7M y/y, driven by SG&A jumps for sales ramp-up, while R&D eased on lower manufacturing costs. Net loss climbed to $12.0M, or $0.03/share, versus $11.5M last year, with the gap tied to interest and forex hits. Cash swelled to $45.0M plus $39.6M in marketable securities after $46.2M from stock raises, against $40.6M debt due 2027 at prime +4.9%; free cash flow not disclosed in the 10-Q. FDA post-approval studies loom large.
8-K
EBR raises $36M via CDI placement
EBR Systems raised U.S. $36.0 million through an institutional placement of 55,900,000 CDIs at A$1.00 each on the ASX, settled May 26, 2025, after deducting $2.2 million in fees. The fully underwritten deal bolsters the company's cash position for ongoing operations. Yet dilution hits existing shareholders hard.
8-K
EBR approves governance upgrades
EBR Systems stockholders approved key governance measures at their May 21, 2025 annual meeting, including an amendment to the Certificate of Incorporation limiting officer liability under Delaware law, filed May 22. They ratified a prior issuance of 45,568,852 CDIs at A$0.82 each and endorsed amendments to the 2021 Equity Incentive Plan plus option grants totaling US$1,225,000 to executives and directors. This bolsters retention amid growth. No risks disclosed.
10-Q
Q1 FY2025 results
EBR Systems posted a Q1 net loss of $10.6 million, up 15% year-over-year from $9.2 million, driven by a 101% surge in general and administrative expenses to $4.4 million amid commercialization preparations, while research and development dipped 15% to $5.4 million thanks to capitalized pre-launch inventory. Operating cash burn hit $13.6 million, offset by $17.9 million from marketable securities maturities, leaving $50.2 million in cash and equivalents at quarter-end. Debt stands steady at $41.8 million with Runway Growth Finance, maturing June 2027, and the company remains covenant-compliant. FDA approval of the WiSE CRT System on April 11, 2025, unlocks U.S. commercial launch, yet going concern doubts linger without fresh capital. Competition from entrenched cardiac device makers poses a key hurdle.
IPO
Employees
Sector
Industry
BWAY
Brainsway Ltd.
16.87-0.47
CBLL
CeriBell, Inc.
21.99+0.09
CVRX
CVRx, Inc.
8.32+0.14
ELMD
Electromed, Inc.
29.88+0.28
EMED
Electromedical Technologies, In
0.00+0.00
EW
Edwards Lifesciences Corporatio
85.32+1.94
HSCS
HeartSciences Inc.
2.31-0.16
NMTC
NeuroOne Medical Technologies C
0.71+0.05
NPCE
Neuropace, Inc.
15.88-0.04
VTAK
Catheter Precision, Inc.
2.19-0.04